The number of people affected by SARS-CoV-2 virus and contracting the coronavirus disease (COVID) continues to increase worldwide. While everyone eagerly awaits the discovery of a vaccine to help curb this pandemic, there will still be a few more months before a vaccine is approved and available in the market. In the interim, it is imperative to identify treatment modalities that can help improve outcomes for COVID infected patients as well as reduce mortality.

References

1. Hung IF., et al. “Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19:an open-label, randomized, phase 2 trial”. Lancet (2020).
2. National Institutes of Health. NIH Clinical Trial Testing Antiviral Remdesivir Plus Anti-Inflammatory Drug Baricitinib for COVID-19 Begins (2020).
3. CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir (2020).
4. National Institutes of Health. U.S. National Library of Medicine (2020).

Citation

Citation: Loposso Nkumu Matthieu., et al. “The Management of Obstetric Fistulae: A 5-Year Integrated Approach Decreases the Incidence in a Health District of DRC".Acta Scientific Medical Sciences 4.8 (2020): 01.

Copyright

Copyright: © 2020 Loposso Nkumu Matthieu., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.